LCN2 and type 2 diabetes mellitus: Shimomura et al. reported that urinary neutrophil gelatinase-associated lipocalin (NGAL), which is a tubular damage marker, tended to be decreased after the administration of tofogliflozin in 14 non-albuminuric patients with type 2 diabetes [33].